These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 21343467

  • 1. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.
    Clark C, McGhee P, Appelbaum PC, Kosowska-Shick K.
    Antimicrob Agents Chemother; 2011 May; 55(5):2344-51. PubMed ID: 21343467
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
    Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS, Flamm RK, Jones RN.
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018.
    Jean SS, Lee WS, Ko WC, Hsueh PR.
    J Microbiol Immunol Infect; 2021 Aug; 54(4):627-631. PubMed ID: 32451293
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS, Mendes RE, Farrell DJ, Flamm RK, Jones RN.
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
    Pfaller MA, Flamm RK, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
    [Abstract] [Full Text] [Related]

  • 12. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
    Flamm RK, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):437-42. PubMed ID: 24582578
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M, Browne FA, Jacobs MR, Appelbaum PC.
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [Abstract] [Full Text] [Related]

  • 18. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
    Farrell DJ, Flamm RK, Jones RN, Sader HS.
    Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S, Blais J, Hoang M, Dinh C, Cotter D, Bond E, Gannon C, Park C, Malouin F, Dudley MN.
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.